Canada NewsWire Canada
Statement from the Chief Public Health Officer of Canada on July 25, 2020 - Canada NewsWire
/CNW/ - In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have...
OTTAWA, ON, July 25, 2020 /CNW/ - In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 113,206 cases of COVID-19 in Canada, including 8,881 deaths. 87% of people have now recovered. Labs across Canada have tested over 3,717,483 people for COVID-19 to date. Over the past week, an average of 44,000 people were tested daily, with 1% testing positive and an average of over 485 cases being reported daily from across the country. After months of staying home, many of us may be experiencing a bit of COVID-19 fatigue and backsliding on some important personal public health practices, like maintaining physical distancing from those outside our social bubble. The biggest cause of concern is the recent uptick of cases across the country. As social and economic spaces open up, we do expect to see an increase in cases. The key is to identify and test cases rapidly, and conduct contact tracing in a timely way so that we can immediately stop any outbreaks and ongoing transmission.Our goal in public health is to reduce cases, and reduce instances of severe illness and death during this pandemic. Canadians helped our country to successfully flatten the curve, and Canada's health care system was fortunately not overwhelmed. Canadians have done a great job in following public health measures, such as maintaining physical distancing, practising good hygiene and donning masks when indoors in public spaces. Most importantly, Canadians have been staying home when sick, getting tested, and following the advice of their local public health authorities to keep themselves and others safe. I want Canadians to take to heart that even though we have done well, all it takes is letting our guard down, a lack of understanding, or forgetfulness, to compromise the gains we have achieved together. We can continue to work together to keep cases low in our communities. Our individual actions tangibly make a difference, so we must keep up our good work by continuing to:
- Stay home and away from others if you are sick;
- Clean and disinfect high touch surfaces and objects;
- Wash our hands frequently;
- Cover our coughs and sneezes with a tissue or sleeve;
- Practice physical distancing, and
- Wear a non-medical mask or face covering when physical distancing is difficult to maintain, and/or when mandated by local authorities.
World's 1st inactivated COVID-19 vaccine produces antibodies - Canada NewsWire
/CNW/ -- A news report by Qu Jian from Science and Technology Daily: The Phase I/II clinical trials of the world's first inactivated COVID-19 vaccine,...
BEIJING, June 23, 2020/CNW/ -- A news report by Qu Jian from Science and Technology Daily: The Phase I/II clinical trials of the world's first inactivated COVID-19 vaccine, developed by Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group (Sinopharm), produced antibodies in every participant, it was announced on Tuesday. According to a meeting held simultaneously in Beijing and Henan province on Tuesday, the clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%. According to CNBG, the Phase I/II clinical trials were randomized, double-blind, placebo-controlled clinical studies. On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched in Wuzhi county of Henan province. Under the leadership and guidance of the Henan Center for Disease Control and Prevention, the clinical trials were conducted for 66 consecutive days and obtained data on the safety and efficacy of the COVID-19 inactivated vaccine after the administration of the two injections. The data presented research results on different ages, different procedures, different doses, and different injection times in a relatively comprehensive manner. This is also the clinical COVID-19 vaccine research that has the longest time span, produces the most comprehensive data and obtains the best research results, thus providing scientific and evaluable data for epidemic prevention and control as well as emergency use. CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days. The study focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in the Phase I/II clinical studies have completed two injections. For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%. For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%. In response to recent new cases in Beijing and the discovery of a new genotype of the virus through whole-genome sequencing, some experts worry that for the new genotype, "the vaccine may weaken or even not work." However, Yang Xiaoming, chief scientist of the national "863 Program" vaccine project and chairman of CNBG, told Science and Technology Daily he had noticed the new genotype, but it is "still within the coverage of the vaccine whose Phase I/II unblinding occurred today", so it will not affect the effectiveness of the current inactivated vaccine. CNBG also said that it is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries. It has completed building a high biosafety grade production workshop, which is currently the only COVID-19 vaccine production workshop in the world meeting the requirements of biosafety and GMP standards and capable of meeting the needs of widespread emergency vaccination. SOURCE Science and Technology Daily For further information: Yu Haoyuan, +86-13621282870, [email protected]; Fang Linlin, +86-13911995172, [email protected]
Precision Biomonitoring Receives Funding to Manufacture TripleLock™ SARS CoV-2 Go-Strips - Canada NewsWire
/CNW/ - Precision Biomonitoring, an industry leader in point-of-need molecular detection tools, has announced that is has received approval and funding from...
Innovative Efforts Receive Funding from NGen In Response to Canadian Supply Development Support GUELPH, ON and MISSISSAUGA, ON, June 2, 2020 /CNW/ - Precision Biomonitoring, an industry leader in point-of-need molecular detection tools, has announced that is has received approval and funding from Next Generation Manufacturing Canada (NGen) to support manufacturing needs for the production of its TripleLockTM SARS-CoV-2 Go-Strips. Precision Biomonitoring has secured this funding because of its ongoing efforts to contribute to the development of a Canadian supply of testing kits in response to the COVID-19 pandemic. Precision Biomonitoring is grateful to NGen for its support and is encouraged by its dedication to companies across Canada working to develop resources and tools necessary to protect public health. The funding will enable Precision Biomonitoring to work directly with Canadian manufacturers to rapidly increase production of its SARS-CoV-2 Go-Strips, which will not only support Precision Biomonitoring, but also other Canadian biotech companies working to support the accessibility of molecular testing amidst COVID-19 and into the future. Leveraging the manufacturing capabilities of Canadian manufacturers, Precision Biomonitoring anticipates a production rate capacity of 10,000 units per day or greater. Increased testing capacity will help provide critical testing access and capacity in communities to re-open Canadian economy by helping to create virus-free zones in the workplace to ensure safety of the workers and sustainable operations. "Developing Canadian manufacturing is not only promising for our response efforts for COVID-19, but also provides a strong foundation as we look to expand into the growing mobile DNA applications market," says Thomas. "This includes manufacturing our existing 35 tests for other organisms, helping to establish local sources of supply that Canadians can rely on." Precision Biomonitoring's efforts alongside NGen is an addition to the collaborative relationships Precision Biomonitoring has developed with other Canadian companies and institutions in response to COVID-19, including Canadian Food Inspection Agency, Shared Value Solutions, The Research Institute of St. Joe's (Hamilton), Sunnybrook Health Science Centre and the Canadian National Microbiology Lab. "Advancing Canadian manufacturing enables us to leverage local capabilities to mitigate manufacturing challenges," says John Laughlin, CTO at NGen. "We are proud to help drive these efforts that will position Canada as a world leader in manufacturing point-of-need DNA surveillance and detection tools." About Precision Biomonitoring Founded in 2016 by a team of scientists from the University of Guelph's Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. About NGen NGen is the industry-led community behind Canada's most transformative advanced manufacturing projects. NGen members come from every part of the country and cut across Canada's manufacturing, technology, advanced research, and start-ups sectors. NGen is an objective facilitator of connections and collaboration among its members, identifying opportunities, building capabilities, and supporting advanced manufacturing decisions. NGen's industry collaborations bring together talent, opportunity, funding, and business know-how to reduce risk and help business leaders make better choices. NGen is Canada's Supercluster for Advanced Manufacturing, securing funding from public and private sources, including $230 million in matching dollars from the federal government's Innovation Superclusters Initiative, to support greater private sector investment in advanced manufacturing projects. NGen seeks to add $13.5 billion dollars and 13,500 new jobs to the economy over the next 10 years by growing world-leading advanced manufacturing capabilities in Canada. SOURCE Precision Biomonitoring For further information: Media Contact: Meredith Adams, 416-459-7086, [email protected]